Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Vincristine as Initial Treatment for Retinoblastoma
NCT00002794Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Feb 1996
- Primary completion
- Jun 2001
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and vincristine in retinoblastoma (Rb), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Objective Response Rate at 24 weeks. Started Feb 1996; status: completed.
02
Drugs
carboplatinvincristine
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT00002794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002794.